We have a great conversation for you this week on the OIS Podcast: Paul Karpecki, OD, FAAO, joins Kim Brazzell, PhD and Chief Medical Officer at Kala Pharmaceuticals, to discuss Kim’s experience developing EYSUVIS, the first FDA-approved prescription therapy specifically developed to address the short-term treatment needs of people living with dry eye disease.

Kim gives us tips for navigating the approval process and shares lessons learned since he started working in the space. You don’t want to miss this episode. Press play now!